Abstracts tagged "Biologics"

Abstract Number: 618 • 2017 ACR/ARHP Annual Meeting
Secukinumab Sustains Individual Clinical Responses over Time in Patients with Psoriatic Arthritis: 2-Year Results from a Phase 3 Trial
Paul Emery¹, Iain B. McInnes², Philip J Mease³, Michael Schiff⁴, Luminita Pricop⁵, Steven Shen⁵, Zailong Wang⁵ and Corine Gaillez⁶, ¹NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ²University of Glasgow, Glasgow, United Kingdom, ³Swedish Medical Center and University of Washington, Seattle, WA, ⁴University of Colorado, Denver, CO, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Achieving, sustaining, and improving clinical responses to biologics in PsA are important parts of EULAR and GRAPPA recommendations aimed to optimize treatment goals.1,2 Here…
Abstract Number: 1423 • 2017 ACR/ARHP Annual Meeting
Patterns of Prednisone Use in US Patients with Rheumatoid Arthritis Initiating Treatment with Tocilizumab in Routine Clinical Practice
Dimitrios A. Pappas¹, Carol J. Etzel², Jennie Best³, Steve Zlotnick³, Taylor Blachley², Gioia Persuitte² and Joel Kremer⁴, ¹Columbia University, New York, NY, ²Corrona, LLC, Southborough, MA, ³Genentech, Inc., South San Francisco, CA, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: There are limited data regarding the impact of tocilizumab (TCZ) treatment on prednisone use in patients with rheumatoid arthritis (RA). The objective of this…
Abstract Number: 1554 • 2017 ACR/ARHP Annual Meeting
Discontinuation and Switching Patterns By TNFi Line of Therapy in Patients with Psoriatic Arthritis—Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J Mease¹, Chitra Karki², Mei Liu², YouFu Li³, Peter Hur⁴ and Jeffrey D. Greenberg⁵, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Southborough, MA, ³University of Massachusetts Medical School, Worcester, MA, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵New York University School of Medicine, New York, NY
Background/Purpose: Few real-world studies have characterized the use of first- vs second-line tumor necrosis factor inhibitors (TNFis) in US patients with psoriatic arthritis (PsA). This…
Abstract Number: 2492 • 2017 ACR/ARHP Annual Meeting
The Long-Term Safety and Durability of Response of Chs-0214, a Proposed Biosimilar to Etanercept: An Open-Label Safety Extension Study
Ingrid Louw¹, Alan J. Kivitz², Tsutomu Takeuchi³, Yoshiya Tanaka⁴, Satoshi Nakashima⁵, Jennifer Hodge⁶, Hong Tang⁶, Paula O'Connor⁶ and Barbara Finck⁶, ¹Panorama Medical Centre, Cape Town, South Africa, ²Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ³Keio University School of Medicine, Tokyo, Japan, ⁴School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁵Daiichi Sankyo, Tokyo, Japan, ⁶Coherus BioSciences, Inc., Redwood City, CA
Background/Purpose: CHS-0214 is a proposed biosimilar to etanercept for the treatment of rheumatoid arthritis and other auto-immune diseases. Two randomized, double-blind studies demonstrated equivalence of…
Abstract Number: 202 • 2017 ACR/ARHP Annual Meeting
Analysis of Provider-to-Provider Variability in the Use of Biologics: Data from the Rheumatology Informatics System for Effectiveness Registry
Douglas White¹, Michael Evans², Gabriela Schmajuk³, Rachel Myslinski⁴, Salahuddin Kazi⁵ and Jinoos Yazdany⁶, ¹Gundersen Health System, Onalaska, WI, ²University of California San Francisco, San Francisco, CA, ³San Francisco VA Medical Center, University of California San Francisco, San Francisco, CA, ⁴Practice, Advocacy, & Quality, American College of Rheumatology, Atlanta, GA, ⁵University of Texas Southwestern, Dallas, TX, ⁶Medicine/Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Variations in biologic prescribing habits by rheumatology providers may account in part for variability in direct cost of care for patients with rheumatoid arthritis…
Abstract Number: 621 • 2017 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvement in Major and Moderate Response of Disease Activity Index for Psoriatic Arthritis (DAPSA): 2-Year Results from a Phase 3 Study
Josef S. Smolen¹, Philip J Mease², Christopher T. Ritchlin³, Tore K Kvien⁴, Luminita Pricop⁵, Todd Fox⁶, Lawrence Rasouliyan⁷, Steffen Jugl⁶ and Corine Gaillez⁶, ¹Medical University of Vienna, Vienna, Austria, ²Swedish Medical Center and University of Washington, Seattle, WA, ³Division of Allergy, Immunology and Rheumatology, School of Medicine and Dentistry, Division of Allergy, Immunology and Rheumatology, School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA, Rochester, NY, ⁴Diakonhjemmet Hospital, Oslo, Norway, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷RTI Health Solutions, Barcelona, Spain
Background/Purpose: DAPSA score is a validated tool to measure disease activity states and response criteria, focusing on peripheral joint involvement in patients (pts) with PsA.1…
Abstract Number: 1433 • 2017 ACR/ARHP Annual Meeting
Tailoring Second-Line Biologic Therapy in Rheumatoid Arthritis: New Findings on the Usefulness of Antibody Status to Optimise Drug Selection
Muhammad Shipa¹, Maria Di Cicco², Emese Balogh², Aneela Mian³, Dev Mukerjee⁴ and Euthalia Roussou², ¹Rheumatology and General internal Medicine, North Middlesex University Hospital NHS trust, London, United Kingdom, ²Barking Havering and Redbridge University hospitals NHS Trust, London, United Kingdom, ³Rheumatology, King's College London, London, United Kingdom, ⁴Rheumatology, North Middlesex University Trust, London, United Kingdom
Background/Purpose: Treatment of rheumatoid arthritis (RA) has been revolutionized by the introduction of Tumour Necrosis Factor alpha inhibitors (TNFi). However a significant proportion of patients…
Abstract Number: 1785 • 2017 ACR/ARHP Annual Meeting
Serious or Opportunistic Infections in Infants Born to Pregnant Women with Rheumatoid Arthritis and Treated with a Biologic Medication
Christina D Chambers¹, Diana L Johnson², Yunjun Luo³, Ronghui Xu⁴ and Kenneth L Jones³, ¹Pediatrics and Family Medicine and Public Health, University of California San Diego, La Jolla, CA, ²Department of Pediatrics, University of California, San Diego, La Jolla, CA, ³Pediatrics, University of California San Diego, La Jolla, CA, ⁴Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, CA
Background/Purpose: Use of biologic therapies for rheumatoid arthritis (RA) in pregnancy is common. There is theoretical concern that these medications could interfere with postnatal…
Abstract Number: 2520 • 2017 ACR/ARHP Annual Meeting
Incidence of Extra-Articular Manifestations in Psa and As Patients Treated with Golimumab in Canadian Real-World
Michelle Teo¹, Derek Haaland², John Kelsall³, Isabelle Fortin⁴, Pauline Boulos⁵, Raman Rai⁶, Sanjay Dixit⁷, B Haraoui⁸, Dalton Sholter⁹, Eliofotisti Psaradellis¹⁰, Emmanouil Rampakakis¹⁰, Brendan Osborne¹¹, Francois Nantel¹¹ and Allen J Lehman¹², ¹Balfour Medical Clinic, Penticton, BC, Canada, ²Rheumatology, Clinical Immunology & Allergy, McMaster University, Barrie, ON, Canada, ³Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁴Centre de Rhumatologie De l’Est du Quebec, Rimouski, QC, Canada, ⁵Rheumatology, McMaster University, Hamilton, ON, Canada, ⁶Private Practice, Hamilton, ON, Canada, ⁷Rheumatology, McMaster University Hamilton, Burlington, ON, Canada, ⁸Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, ⁹Rheumatology Associates, Edmonton, AB, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹²Janssen Inc., Toronto, ON, Canada
Background/Purpose: Spondyloarthropathies (SpA) encompass a heterogeneous group of chronic inflammatory diseases affecting axial and peripheral joints. Besides articular symptoms, patients also experience extra-articular manifestations (EAMs)…
Abstract Number: 311 • 2017 ACR/ARHP Annual Meeting
Total Ankle Arthroplasty for Rheumatoid Arthritis Cases in This Biologics Era: Mid to Long-Term Follow-up
Makoto Hirao¹, Jun Hashimoto², Hideki Tsuboi³, Kosuke Ebina⁴ and Hideki Yoshikawa⁵, ¹Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Suita, Japan, ²Rheumatology/Orthopaedics, Osaka-Minami Medical Ctr, Kawachinagano, Japan, ³Orthopaedics/Rheumatology, Osaka Rosai Hospital, Sakai, Japan, ⁴Orthopaedics, Osaka University Graduate School of Medicine, Suita, Japan, ⁵Department of Orthopedics, Osaka University Graduate School of Medicine, Suita Osaka, Japan
Background/Purpose: Outcomes after total ankle arthroplasty (TAA) combined with additive techniques (augmentation of bone strength, control of soft tissue balance, adjustment of the loading axis)…
Abstract Number: 622 • 2017 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Minimal Disease Activity (MDA) and Remission Related to Disease Activity Index for Psoriatic Arthritis (DAPSA): 2-Year Results from a Phase 3 Study
Laura C Coates¹, Peter Nash², Tore Kvien³, Laure Gossec⁴, Philip J Mease⁵, Lawrence Rasouliyan⁶, Luminita Pricop⁷, Steffen Jugl⁸, Kunal Gandhi⁷, Corine Gaillez⁸ and Josef S. Smolen⁹, ¹University of Oxford, Leeds, Great Britain, ²University of Queensland, Brisbane, Australia, ³Diakonhjemmet Hospital, Oslo, Norway, ⁴UPMC, University Paris 06, Pitié-Salpétrière Hospital, Paris, France, ⁵Swedish Medical Center and University of Washington, Seattle, WA, ⁶RTI Health Solutions, Barcelona, Spain, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria
Background/Purpose: Very low disease activity (VLDA) or remission (REM) and alternatively, minimal disease activity (MDA) or low disease activity (LDA) are optimal targets to be…
Abstract Number: 1447 • 2017 ACR/ARHP Annual Meeting
Smoking Reduces Efficacy of Biologics Differently By Target Cytokines in Rheumatoid Arthritis
Kentaro Kuzuya¹, Yukihiko Saeki², Jun Hashimoto³, Shirou Oshima⁴, Masato Matsushita⁵, Souichirou Tuji⁴, Yoshinori Harada⁶, Maiko Yoshimura⁶, Satoru Teshigawara⁶ and Hidetoshi Matsuoka⁴, ¹Rheumatology and Allegology, Osaka-Minami Medical Ctr, Kawachinagano, Japan, ²Dept of Clinical research, Osaka-Minami Medical Ctr, Osaka, Japan, ³Rheumatology/Orthopaedics, Osaka-Minami Medical Ctr, Kawachinagano, Japan, ⁴Division of Rheumatology, Osaka-Minami Medical Ctr, Osaka, Japan, ⁵Rheumatology, Osaka-Minami Medical Ctr, Osaka, Japan, ⁶Osaka-Minami Medical Ctr, Kawachinagano, Japan
Background/Purpose: Biologiccs (Bio) have shown outstanding efficacy and became one of the most effective drugs in the treatment of RA. However, several issues remain, including…
Abstract Number: 1818 • 2017 ACR/ARHP Annual Meeting
Development of Abatacept- and Adalimumab-Specific Predictive Models of Response to Therapy in RA Using Data from a Head-to-Head Study
S Bandyopadhyay¹, MA Maldonado¹, R Ammar¹, Michael Schiff², Michael Weinblatt³, Roy Fleischmann⁴ and SE Connolly¹, ¹Bristol-Myers Squibb, Princeton, NJ, ²University of Colorado, Denver, CO, ³Brigham and Women’s Hospital, Boston, MA, ⁴University of Texas Southwestern Medical Centre, Dallas, TX
Background/Purpose: Highly effective, targeted DMARD therapies with different mechanisms of action are available for RA. Translating precision medicine into clinical practice requires treatment-specific predictive models,…
Abstract Number: 2523 • 2017 ACR/ARHP Annual Meeting
The Prevalence, Incidence and Associated Factors for Liver Abnormalities in Psoriatic Arthritis: Resutls from a Longitudinal Observational Cohort
Rattapol Pakchotanon¹, Justine (Yang) Ye¹, Richard J. Cook², Vinod Chandran³ and Dafna D Gladman³, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ³Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease which affects the skin and musculoskeletal system. PsA patients frequently suffer from comorbidities: cardiovascular disease, metabolic…
Abstract Number: 344 • 2017 ACR/ARHP Annual Meeting
Real World Clinical Trial Comparing the Patient Reported Outcomes Measurement Information System Short Forms and Profiles to CDAI Disease Classification in Rheumatoid Arthritis Patients
Jeffrey R. Curtis¹, Sergio Schwartzman², Shelly Kafka³, Dennis Parenti³, Shawn Black³, Stephen Xu⁴, Wayne Langholff⁴ and Clifton O. Bingham III⁵, ¹Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ²Weill Cornell Medical College, New York, NY, ³Janssen Scientific Affairs, LLC, Horsham, PA, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Rheumatology, Johns Hopkins University, Baltimore, MD
Background/Purpose: Patient (Pt) reported outcomes (PROs) play a role in overall disease evaluation, therapeutic response assessment and care of rheumatoid arthritis (RA) patients (Pts). The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.